Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $59,518.34 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $0.98, for a total value of $59,518.34. Following the completion of the transaction, the insider owned 5,065,037 shares of the company’s stock, valued at approximately $4,963,736.26. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $57,261.98.
• On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $20,074.23.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.
• On Tuesday, November 18th, Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $57,325.20.

Werewolf Therapeutics Stock Down 8.3%

Shares of NASDAQ HOWL traded down $0.08 during trading on Monday, reaching $0.92. 638,958 shares of the stock were exchanged, compared to its average volume of 503,042. The business’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.34. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The company has a market capitalization of $44.50 million, a price-to-earnings ratio of -0.57 and a beta of 0.74. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on HOWL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics in the second quarter valued at approximately $48,000. Nuveen LLC bought a new position in Werewolf Therapeutics during the first quarter worth $71,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics during the second quarter worth approximately $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.